1. Bulgaria Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sopharma AD

Sopharma AD

12.85
PLN
+0.55
(+4.47%)
7.47P/E
Dec 02Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.05
3.38
6.77
6.8
8.09
4.78
10.18
5.83
12.79
13.69
7.3
12.96
3.87
15.69
Basic EPS, GAAP
0.12
0.08
0.17
0.39
0.32
0.11
0.69
0.12
0.71
0.59
0.37
0.46
0.19
0.78
Free Cash Flow per Basic Share
-0.15
-0.1
-0.17
-0.14
-0.18
-0.11
-0.35
-0.11
-0.22
-0.19
-0.17
-0.74
-0.21
-0.86
Dividend per Share
0.04
0.05
0.03
0.09
0.12
0.09
0.03
0.09
- -
- -
0.28
1.03
0.02
0.08
Book Value per Share
1.45
1.49
3.14
3.55
3.74
1.92
4.43
2.24
5.31
5.81
2.37
4.94
0.92
5.26
Tangible Book Value per Share
1.34
1.4
2.86
3.2
3.05
1.58
3.96
1.95
4.76
5.38
2.18
3.35
0.67
4.34
Basic Weighted Avg Shares
127
127
129
129
126
126
126
126
125
121
131
164
343
166
Sales/Revenue/Turnover
388
428
875
877
1,017
601
1,282
733
1,603
1,663
954
2,129
1,329
2,610
Operating Margin (%)
8.74
6.43
6.48
5.8
6.18
3.93
4.77
3.77
4.52
5.35
5.25
4.07
5.6
5.6
Depreciation Expense
12
14
26
29
30
17
44
24
53
52
28
59
40
79
Net Income, GAAP
15
10
21
51
40
14
87
15
89
71
49
76
66
129
Effective Tax Rate (%)
13.6
17.4
18.04
11.6
12.57
13.31
4.59
19.6
6.02
10.28
10.18
12.65
13.64
13.64
Profit Margin (%)
3.86
2.4
2.44
5.77
3.93
2.4
6.79
2.07
5.58
4.28
5.12
3.58
4.95
4.95
Working Capital
52
54
119
128
115
49
65
35
147
165
90
78
117
229
LT Debt
30
24
41
29
52
22
83
43
84
80
65
152
106
209
Total Equity
211
220
458
491
503
259
576
289
659
717
383
843
497
977
Return on Invested Capital (%)
5.76
4.32
6.54
8.28
9.45
4.95
6.4
4.41
6.87
10.72
8.47
6.21
8.61
8.61
Return on Capital (%)
3.37
2.31
3.91
10.24
7.09
4.04
11.05
4.48
9.83
9.62
9.8
6.99
9.65
10.6
Return on Common Equity (%)
5.65
3.74
5.48
15.25
11.34
5.99
16.86
5.37
14.91
13.75
13.33
9.81
14.64
17.2

Capital Structure

BGN

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
380
416
405
LT Borrowings
150
120
112
LT Finance Leases
95
97
96
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
170
519
526
Market Capitalization
383
972
965

Working Capital

BGN

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
1,008
1,037
1,094
Cash, Cash Equivalents & STI
35
33
72
Accounts Receivable, Net
408
411
413
Inventories
458
487
505
Total Current Liabilities
777
791
865
Payables & Accruals
- -
- -
- -
ST Debt
380
416
405
Deferred Revenue
- -
- -
- -

Growth Rates

BGN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.3%
33.88%
-41.01%
Free Cash Flow
60.26%
98.41%
-39.68%
Net Income, GAAP
95.26%
96%
-13.79%
Sales/Revenue/Turnover
21.12%
33.08%
-37.57%
Total Cash Common Dividend
33,284.72%
66,496.16%
-95.89%

Quarterly Revenue

BGN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
509
489
539
301
2,129
2025
327
319
636
358
1,329
2026
353
365
- -
- -
- -

Quarterly Earnings Per Share

BGN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
- -
- -
- -
0.46
2025
0.12
- -
- -
- -
0.19
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

BGN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.03
2025
- -
- -
- -
- -
0.02
2026
0.03
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ognian Ivanov Donev
Full Time Employees
6,005
Sector
Health technology
Industry
Pharmaceuticals: major
Address
16 Iliensko shosse street Sofia SC Bulgaria 1220
IPO Date
Jan 20, 1998
Website
sopharma.bg
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sopharma AD (SFA: Bulgarian Stock Exchange; SPH.WA: Warsaw Stock Exchange) manufactures and markets generic pharmaceuticals, plant-based medicines, over-the-counter products, prescription drugs, veterinary medicines, food supplements, medicinal cosmetics including plasters, bandages, herbal cosmetics and sanitary-hygiene products, medical devices such as hemodialysis concentrates, non-sterile medicinal products comprising powders, skin solutions and oral tinctures, and chemical pharmaceutical substances; the company pursues research, development, engineering and implementation in phytochemistry, chemistry and pharmacy, with production across multiple facilities in Bulgaria including Sofia for solid, ampoule, suppository forms and gamma sterilization, Sandanski for solid and liquid forms plus medical devices, Vrabevo for solid, liquid and semi-solid forms, Veliko Tarnovo for non-sterile liquids, alcohols and tinctures, Kazanlak for phytochemical and synthetic active ingredients, and Sliven for veterinary products. The company operates through Sopharma Group, which encompasses ninety subsidiaries focused on manufacturing, distribution via Sopharma Trading AD in Bulgaria and Serbia offering over 15,000 health-related items, and sales in more than 40 countries emphasizing Eastern and Southeastern Europe, Russia, Ukraine, Kazakhstan and Poland; founded in 1933 and headquartered at 16 Iliensko Shosse, Sofia, Bulgaria, Sopharma AD maintains leading positions in cardiology, gastroenterology, pain management, cough and cold, immunology, dermatology, respiratory tract and asthma, neurology, psychiatry, urology, gynecology, nephrology, surgery, orthopedics and traumatology therapeutic areas, with key brands like Tabex, Carsil, Broncholitin and Analgin. In October 2024, Sopharma AD initiated a strategic acquisition of a pharmaceutical portfolio including 68 marketing authorizations and 14 well-known brands covering consumer healthcare and prescription products in sex hormones, urologicals and antivirals across 10 traditional markets, completing the initial due diligence stage by late November 2024 with a EUR 40 million payment financed by own funds, advancing in multiple phases subject to conditions precedent to bolster its regional presence.